Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Exploring the Potential of ctDNA-MRD for Recurrence Surveillance and Prognostic Evaluation in High-risk Endometrial Cancer

NCT06341855 is registered in ClinicalTrials.gov with The First Hospital of Jilin University as lead sponsor.

NCT NCT06341855
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06341855 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Exploring the Potential of ctDNA-MRD for Recurrence Surveillance and Prognostic Evaluation in High-risk Endometrial Cancer
Lead sponsor
The First Hospital of Jilin University
Phase
Not applicable
Overall status
Unknown status
Start date
January 25, 2024
Completion date
January 30, 2026
Enrollment
100 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

endometrial cancer